Table of Contents
Lung Cancer International
Volume 2015 (2015), Article ID 590148, 7 pages
http://dx.doi.org/10.1155/2015/590148
Research Article

Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy

1Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6
2Department of Medicine, Queen’s University, 102 Stuart Street, Kingston, ON, Canada K7L 2V6
3The Ottawa Hospital Research Institute, 725 Parkdale Avenue, Ottawa, ON, Canada K1Y 4E9

Received 28 November 2014; Revised 14 January 2015; Accepted 18 January 2015

Academic Editor: Akira Iyoda

Copyright © 2015 Mathieu D. Saint-Pierre et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Howlader, A. M. Noone, M. Krapcho et al., SEER Cancer Statistics Review, 1975–2011, National Cancer Institute, Bethesda, Md, USA, 2014, http://seer.cancer.gov/csr/1975_2011/.
  2. Statistics Canada, Table 103-0550—New cases of primary cancer (based on the February 2014 CCR tabulation file), by cancer type, age group and sex, Canada, provinces and territories, annual, CANSIM (database).
  3. B. P. Lanphear and C. R. Buncher, “Latent period for malignant mesothelioma of occupational origin,” Journal of Occupational Medicine, vol. 34, no. 7, pp. 718–721, 1992. View at Google Scholar · View at Scopus
  4. B. M. Robinson, “Malignant pleural mesothelioma: an epidemiological perspective,” Annals of Cardiothoracic Surgery, vol. 1, no. 4, pp. 491–496, 2012. View at Google Scholar
  5. A. S. Tsao, I. Wistuba, J. A. Roth, and H. L. Kindler, “Malignant pleural mesothelioma,” Journal of Clinical Oncology, vol. 27, no. 12, pp. 2081–2090, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. E. Herndon II, M. R. Green, A. P. Chahinian, J. M. Corson, Y. Suzuki, and N. J. Vogelzang, “Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B,” Chest, vol. 113, no. 3, pp. 723–731, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. J. G. Edwards, K. R. Abrams, J. N. Leverment, T. J. Spyt, D. A. Waller, and K. J. O'Byrne, “Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems,” Thorax, vol. 55, no. 9, pp. 731–735, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Curran, T. Sahmoud, P. Therasse, J. van Meerbeeck, P. E. Postmus, and G. Giaccone, “Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience,” Journal of Clinical Oncology, vol. 16, no. 1, pp. 145–152, 1998. View at Google Scholar · View at Scopus
  9. A. Bottomley, C. Coens, F. Efficace et al., “Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma,” Journal of Clinical Oncology, vol. 25, no. 36, pp. 5770–5776, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. P. van Meerbeeck, R. Gaafar, C. Manegold et al., “Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 6881–6889, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. N. J. Vogelzang, J. J. Rusthoven, J. Symanowski et al., “Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma,” Journal of Clinical Oncology, vol. 21, no. 14, pp. 2636–2644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. M. F. Muers, R. J. Stephens, P. Fisher et al., “Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial,” The Lancet, vol. 371, no. 9625, pp. 1685–1694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Treasure, L. Lang-Lazdunski, D. Waller et al., “Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study,” The Lancet Oncology, vol. 12, no. 8, pp. 763–772, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. V. W. Rusch, D. Giroux, C. Kennedy et al., “Initial analysis of the international association for the study of lung cancer mesothelioma database,” Journal of Thoracic Oncology, vol. 7, no. 11, pp. 1631–1639, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. S. R. Kalmadi, C. Rankin, M. J. Kraut et al., “Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810),” Lung Cancer, vol. 60, no. 2, pp. 259–263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Pinto, A. Marino, V. D. P. Manzini et al., “Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1),” Lung Cancer, vol. 52, no. 2, pp. 199–206, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. D. A. Fennell, J. P. C. Steele, J. Shamash et al., “Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma,” Lung Cancer, vol. 47, no. 2, pp. 277–281, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. C. W. Lee, N. Murray, H. Anderson, S. C. Rao, and W. Bishop, “Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia,” Lung Cancer, vol. 64, no. 3, pp. 308–313, 2009. View at Publisher · View at Google Scholar · View at Scopus